Hemophilia A is an inherited X-linked bleeding disease with incidence of one in 5000 male birth. Treatment of Hemophilia is extremely expensive especially for high titer inhibitory patients. The current standard of care in Iran primarily involves on demand usage of BPAs like rFVIIa. This study evaluate the cost-effectiveness of Emicizumab compared with rFVIIa. A life time markov model with societal perspective run for patients with different age and different ABRs. Clinical efficacy, safety, route of administration and dosage considerations were extrapolated from literature for both Emicizumab and rFVIIa. Clinical management practice in Iran was obtained from clinician interviews and audit data from Mofid Hospital. Costs calculated based on official local tariff prices and utilities were taken from publications. Age dependent weight and adjusted life table were used. One way deterministic sensitivity analysis and budget impact analysis were performed. Life time delta cost for one patient with ABR 25 and age 12 at starting point (base case) was €-2.15 million and delta QALY was 6.85. Delta cost for patient with ABR 15 and age 12 was € -0.56 million and for ABR 14 was €-46472, for ABR 13 and below the cost was positive with a higher ICER. In patients with age 2 at start point, ABR 15, and in patients with age 20, ABR 16, resulted to delta cost of €255045 and €75707 and delta QALY of 8.6 & 6.7 respectively. The results sensitivity to each parameter change evaluated and in base case, Emicizumab remained dominant in all scenarios. The budget impact for one year use of Emicizumab for each patient with ABR 15, 20 and 25 were €-47876, €-94465 and €-128150 respectively. Emicizumab prophylaxis is a dominant choice for Iranian inhibitory hemophilia patients with ABR 16 and above with considerable cost saving.
Read full abstract